CN101820754A - 用于增强认知功能的组合物与方法 - Google Patents

用于增强认知功能的组合物与方法 Download PDF

Info

Publication number
CN101820754A
CN101820754A CN200880110329A CN200880110329A CN101820754A CN 101820754 A CN101820754 A CN 101820754A CN 200880110329 A CN200880110329 A CN 200880110329A CN 200880110329 A CN200880110329 A CN 200880110329A CN 101820754 A CN101820754 A CN 101820754A
Authority
CN
China
Prior art keywords
animal
composition
mcts
lcpufa
norc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880110329A
Other languages
English (en)
Chinese (zh)
Inventor
潘元龙
M·沃尔德伦
B·T·拉尔森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nestec SA
Original Assignee
Societe dAssistance Technique pour Produits Nestle SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40526561&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101820754(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Societe dAssistance Technique pour Produits Nestle SA filed Critical Societe dAssistance Technique pour Produits Nestle SA
Publication of CN101820754A publication Critical patent/CN101820754A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/158—Fatty acids; Fats; Products containing oils or fats
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A23K50/42—Dry feed
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A23K50/48—Moist feed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Birds (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CN200880110329A 2007-10-04 2008-10-02 用于增强认知功能的组合物与方法 Pending CN101820754A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99766507P 2007-10-04 2007-10-04
US60/997,665 2007-10-04
PCT/US2008/011424 WO2009045481A1 (en) 2007-10-04 2008-10-02 Compositions and methods for enhancing cognitive function

Publications (1)

Publication Number Publication Date
CN101820754A true CN101820754A (zh) 2010-09-01

Family

ID=40526561

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880110329A Pending CN101820754A (zh) 2007-10-04 2008-10-02 用于增强认知功能的组合物与方法

Country Status (16)

Country Link
US (1) US20100292330A1 (enExample)
EP (1) EP2194781B2 (enExample)
JP (1) JP5931337B2 (enExample)
CN (1) CN101820754A (enExample)
AU (3) AU2008307494B2 (enExample)
BR (1) BRPI0818301B1 (enExample)
CA (1) CA2701179C (enExample)
ES (1) ES2664777T5 (enExample)
HU (1) HUE037628T2 (enExample)
MX (1) MX2010003568A (enExample)
NO (1) NO2194781T3 (enExample)
PL (1) PL2194781T5 (enExample)
RU (1) RU2507742C2 (enExample)
TR (1) TR201807131T4 (enExample)
WO (1) WO2009045481A1 (enExample)
ZA (1) ZA201003084B (enExample)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103442725A (zh) * 2011-01-25 2013-12-11 雀巢产品技术援助有限公司 治疗、减轻或预防动物的视觉系统衰退的方法和组合物
CN103609752A (zh) * 2013-12-02 2014-03-05 内蒙古伊利实业集团股份有限公司 一种改善脑部认知功能的组合物及其制备方法与应用
CN105663109A (zh) * 2015-12-29 2016-06-15 浙江旭晨医药科技有限公司 甘油三酯类化合物在制备治疗神经退行性疾病药物中的应用
CN106793800A (zh) * 2014-10-10 2017-05-31 雀巢产品技术援助有限公司 用于增强运动性或活动性或者治疗体弱的组合物和方法
CN106998748A (zh) * 2014-12-08 2017-08-01 雀巢产品技术援助有限公司 用于治疗癫痫的包含中链甘油三酯的组合物和方法
CN107708446A (zh) * 2015-06-22 2018-02-16 雀巢产品技术援助有限公司 用于增强动物体内神经形成的组合物和方法
CN108289873A (zh) * 2015-12-04 2018-07-17 雀巢产品技术援助有限公司 用于改善认知的方法
CN109689041A (zh) * 2016-09-29 2019-04-26 雀巢产品技术援助有限公司 作为未患痴呆患者的神经保护剂的ω-3脂肪酸和胆碱
CN110475553A (zh) * 2017-04-11 2019-11-19 雀巢产品有限公司 减轻未患痴呆的个体的认知衰老的组合物和方法
CN119344377A (zh) * 2024-12-27 2025-01-24 内蒙古伊利实业集团股份有限公司 一种有助于提升和/或改善个体社会行为的营养组合物及其应用

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060280721A1 (en) 2003-06-03 2006-12-14 The Gov Of Usa Represented By Secretary Of Dpt Of Nutritional supplements and therapeutic compositions comprising (r)-3- hydroxybutyrate derivatives
CN101909632A (zh) 2008-01-04 2010-12-08 雀巢产品技术援助有限公司 包含不饱和脂肪酸和一氧化氮释放化合物的组合物及其用于增强认知和相关功能的用途
EP2435563A4 (en) * 2009-05-29 2013-10-02 Univ Columbia MODULATION OF PHOSPHOLIPASE D FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
ES2593880T3 (es) 2009-09-11 2016-12-13 Nestec, S.A. Composiciones y métodos para mejorar las funciones cognitivas y relacionadas en animales
GB201002983D0 (en) * 2010-02-22 2010-04-07 Tdeltas Ltd Nutritinal composition
WO2012044242A1 (en) 2010-09-29 2012-04-05 Procordia Food Ab Use of a food product comprising viscous fibres which has a beneficial effect on cognitive performance.
WO2012125020A1 (en) 2011-03-14 2012-09-20 N.V. Nutricia Method for treating neurotrauma
EP2685962A1 (en) 2011-03-17 2014-01-22 Transdermal Biotechnology, Inc. Topical nitric oxide systems and methods of use thereof
ES2727043T3 (es) * 2011-03-18 2019-10-11 Nestle Sa Composiciones y métodos útiles para mejorar enfermedades relacionadas con la edad
CA2835429A1 (en) * 2011-05-10 2012-11-15 Nestec S.A. Methods and compositions for promoting lean body mass growth
AU2012253701A1 (en) * 2011-05-10 2013-11-21 Nestec S.A. Methods and compositions for preserving lean body mass during weight loss
US8183227B1 (en) 2011-07-07 2012-05-22 Chemo S. A. France Compositions, kits and methods for nutrition supplementation
US8168611B1 (en) 2011-09-29 2012-05-01 Chemo S.A. France Compositions, kits and methods for nutrition supplementation
US8551532B2 (en) 2011-11-02 2013-10-08 Kuwait University Method of making an anti-inflammatory composition
US8871257B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery
US8871261B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Cancer treatments and compositions for use thereof
US8871255B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment of skin and soft tissue infection with nitric oxide
US8871259B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Techniques and systems for treatment of neuropathic pain and other indications
US8871262B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Compositions and methods for treatment of osteoporosis and other indications
US8871258B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment and prevention of learning and memory disorders
US8871260B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and compositions for muscular and neuromuscular diseases
US8871256B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and systems for treatment of inflammatory diseases with nitric oxide
US8871254B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
GB201304467D0 (en) 2013-03-12 2013-04-24 Tdeltas Ltd Compound for use in protecting skin
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9295636B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9724419B2 (en) 2013-03-13 2017-08-08 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9314417B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US20140271938A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9387159B2 (en) 2013-03-13 2016-07-12 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9750787B2 (en) 2013-03-13 2017-09-05 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9849160B2 (en) 2013-03-13 2017-12-26 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9687520B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9241899B2 (en) 2013-03-13 2016-01-26 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9393264B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9393265B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9314423B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US9320758B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9314422B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9295637B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US9339457B2 (en) 2013-03-13 2016-05-17 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US20140271937A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US20140271731A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9314433B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
KR101588247B1 (ko) * 2013-04-17 2016-01-25 경희대학교 산학협력단 뇌졸중 또는 퇴행성 뇌질환 예방 또는 치료용 조성물
WO2015042137A1 (en) * 2013-09-23 2015-03-26 Almendra Americas, LLC Sweetener composition, sweetener products, and methods of sweetening
US9959628B2 (en) * 2014-11-21 2018-05-01 Christopher M. MUTTI Imaging system for object recognition and assessment
US10668041B2 (en) * 2014-12-08 2020-06-02 Societe Des Produits Nestle Sa Compositions and methods comprising medium chain triglycerides for treatment of epilepsy
GB2547903A (en) * 2016-03-01 2017-09-06 Dodson & Horrell Ltd Antioxidant mix for learning
CA3081756A1 (en) 2017-11-17 2019-05-23 Hill's Pet Nutrition, Inc. Compositions comprising omega-3 polyunsaturated and medium chain fatty acids
AU2019280170B2 (en) * 2018-06-07 2024-03-28 Société des Produits Nestlé S.A. Methods and compositions for increasing ketone bodies in animals
EP3806840A4 (en) * 2018-06-15 2022-04-13 Youhealth Biotech, Limited COMPOSITION AND METHODS OF MODULATING ELOVL2
JP7270160B2 (ja) * 2018-08-07 2023-05-10 国立大学法人 香川大学 乳化イサダオイル
US12458617B2 (en) 2019-05-24 2025-11-04 Hill's Pet Nutrition, Inc. Pet food compositions comprising caprylic acid and docosahexaenoic acid and/or eicosapetaenoic acid for use in treating struvite urolithiasis
US20220394999A1 (en) * 2019-12-19 2022-12-15 Hill's Pet Nutrition, Inc. Pet Food Compositions
CN112662800B (zh) * 2020-12-28 2022-12-20 广西大学 水稻耐冷主效qtl cts12的分子标记引物及其标记方法和应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2018A (en) * 1841-03-26 Joseph francis
US5780039A (en) 1992-04-23 1998-07-14 Novartis Nutrition Ag Orally-ingestible nutrition compositions having improved palatability
US5714472A (en) * 1993-12-23 1998-02-03 Nestec Ltd. Enternal formulation designed for optimized nutrient absorption and wound healing
US5723446A (en) * 1993-12-23 1998-03-03 Nestec Ltd. Enteral formulation designed for optimized nutrient absorption and wound healing
US5728678A (en) * 1995-06-06 1998-03-17 Nestec Ltd. Method and composition for providing nutrition to a renal failure patient
US5977138A (en) * 1996-08-15 1999-11-02 Schering Corporation Ether muscarinic antagonists
DE19757414A1 (de) * 1997-12-23 1999-07-01 Nutricia Nv Fettmischung
US7655423B2 (en) 1999-06-14 2010-02-02 Henry Ford Health System Nitric oxide donors for inducing neurogenesis
NZ516513A (en) * 1999-06-14 2004-03-26 Ford Henry Health System Nitric oxide donors for inducing neurogenesis
US20080009467A1 (en) * 2000-05-01 2008-01-10 Accera, Inc. Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimers disease and other diseases resulting from reduced neuronal metabolism
US6835750B1 (en) * 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
US20070179197A1 (en) * 2000-05-01 2007-08-02 Accera, Inc. Compositions and methods for improving or preserving brain function
US20050002992A1 (en) * 2003-06-17 2005-01-06 Mccleary Edward Larry Foods, beverages, condiments, spices and salad dressings with specialized supplements
US6964969B2 (en) 2001-04-19 2005-11-15 Mccleary Edward Larry Composition and method for treating impaired or deteriorating neurological function
AU2002336638A1 (en) * 2001-10-12 2003-04-28 Cornell Research Foundation, Inc. Reversing or preventing premature vascular senescence
NL1019368C2 (nl) * 2001-11-14 2003-05-20 Nutricia Nv Preparaat voor het verbeteren van receptorwerking.
US20030113701A1 (en) * 2001-12-13 2003-06-19 William Gartner Self-scoring method and apparatus for early self-screening of neurological disease
US20040087490A1 (en) * 2002-09-20 2004-05-06 Troup John P. Nutritional compositions
JP4699901B2 (ja) * 2003-09-02 2011-06-15 ジェレックスインターナショナル株式会社 体脂肪代謝機能と燃焼エネルギーの活用機能とを備えているダイエット用添加物質
US8715717B2 (en) * 2003-09-05 2014-05-06 Hill's Pet Nutrition, Inc. Composition for animal consumption
WO2005063050A1 (en) * 2003-12-19 2005-07-14 Abbott Laboratories Method of increasing lean body mass and reducing body fat mass in infants
US20060002985A1 (en) * 2004-07-02 2006-01-05 Zicker Steven C Compositions and methods for decreasing age-related deterioration in mental activities in companion animals
US8324276B2 (en) * 2005-01-24 2012-12-04 Pronova Biopharma Norge As Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
CN1810257A (zh) * 2005-05-26 2006-08-02 钟健琳 活脑素口服液
WO2007022991A1 (en) 2005-08-26 2007-03-01 Nestec S.A. Compositions and methods for improving functional vascular integrity, cellular survival and reducing apoptosis in ischemia or after ischemic episode in the brain
AU2006299665B2 (en) * 2005-09-30 2012-12-13 Nestec S.A. Methods and compositions for improving cognitive function
RU2437656C2 (ru) 2005-12-15 2011-12-27 Нестек С.А. Композиции и способы для сохранения функции головного мозга
PL1800675T4 (pl) 2005-12-23 2012-02-29 Nutricia Nv Kompozycja zawierająca wielonienasycone kwasy tłuszczowe, białka, mangan, i/lub molibden oraz nukleozydy/nukleotydy do leczenia otępienia
WO2009002145A1 (en) † 2007-06-26 2008-12-31 N.V. Nutricia Lipid composition for improving function of brain functioning
CN101909632A (zh) * 2008-01-04 2010-12-08 雀巢产品技术援助有限公司 包含不饱和脂肪酸和一氧化氮释放化合物的组合物及其用于增强认知和相关功能的用途

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103442725A (zh) * 2011-01-25 2013-12-11 雀巢产品技术援助有限公司 治疗、减轻或预防动物的视觉系统衰退的方法和组合物
CN103609752A (zh) * 2013-12-02 2014-03-05 内蒙古伊利实业集团股份有限公司 一种改善脑部认知功能的组合物及其制备方法与应用
CN103609752B (zh) * 2013-12-02 2016-05-25 内蒙古伊利实业集团股份有限公司 一种改善脑部认知功能的组合物及其制备方法与应用
CN106793800A (zh) * 2014-10-10 2017-05-31 雀巢产品技术援助有限公司 用于增强运动性或活动性或者治疗体弱的组合物和方法
CN106998748A (zh) * 2014-12-08 2017-08-01 雀巢产品技术援助有限公司 用于治疗癫痫的包含中链甘油三酯的组合物和方法
CN107708446A (zh) * 2015-06-22 2018-02-16 雀巢产品技术援助有限公司 用于增强动物体内神经形成的组合物和方法
CN108289873A (zh) * 2015-12-04 2018-07-17 雀巢产品技术援助有限公司 用于改善认知的方法
CN105663109A (zh) * 2015-12-29 2016-06-15 浙江旭晨医药科技有限公司 甘油三酯类化合物在制备治疗神经退行性疾病药物中的应用
CN109689041A (zh) * 2016-09-29 2019-04-26 雀巢产品技术援助有限公司 作为未患痴呆患者的神经保护剂的ω-3脂肪酸和胆碱
CN110475553A (zh) * 2017-04-11 2019-11-19 雀巢产品有限公司 减轻未患痴呆的个体的认知衰老的组合物和方法
CN119344377A (zh) * 2024-12-27 2025-01-24 内蒙古伊利实业集团股份有限公司 一种有助于提升和/或改善个体社会行为的营养组合物及其应用

Also Published As

Publication number Publication date
EP2194781A4 (en) 2011-08-24
EP2194781B2 (en) 2021-03-24
EP2194781A1 (en) 2010-06-16
ZA201003084B (en) 2011-10-26
WO2009045481A1 (en) 2009-04-09
NO2194781T3 (enExample) 2018-07-21
AU2016202685B2 (en) 2017-09-21
CA2701179A1 (en) 2009-04-09
MX2010003568A (es) 2010-04-21
AU2008307494B2 (en) 2013-09-05
EP2194781B1 (en) 2018-02-21
RU2507742C2 (ru) 2014-02-27
PL2194781T3 (pl) 2018-07-31
JP2010540636A (ja) 2010-12-24
AU2016202685A1 (en) 2016-05-19
US20100292330A1 (en) 2010-11-18
HUE037628T2 (hu) 2018-09-28
AU2013205916B2 (en) 2016-05-19
PL2194781T5 (pl) 2021-11-15
ES2664777T5 (es) 2021-10-25
AU2013205916A1 (en) 2013-06-06
ES2664777T3 (es) 2018-04-23
TR201807131T4 (tr) 2018-06-21
BRPI0818301B1 (pt) 2022-02-15
RU2010117221A (ru) 2011-11-10
AU2008307494A1 (en) 2009-04-09
BRPI0818301A2 (pt) 2014-10-07
CA2701179C (en) 2021-03-16
JP5931337B2 (ja) 2016-06-08

Similar Documents

Publication Publication Date Title
US11951137B2 (en) Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing cognitive and related functions
AU2016202685B2 (en) Compositions and methods for enhancing cognitive function
US20160101081A1 (en) Compositions and methods for enhancing mobility or activity or treating frailty
AU2015358958B2 (en) Compositions and methods comprising medium chain triglycerides for treatment of epilepsy
BR112017010381B1 (pt) Uso de triglicerídeos de cadeia média para preparação de uma composição alimentícia para acentuar o efeito de fármaco antiepiléptico notratamento de epilepsia em um animal

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20100901